GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Diasorin SpA (OTCPK:DSRLF) » Definitions » Total Stockholders Equity

Diasorin SpA (Diasorin SpA) Total Stockholders Equity

: $1,678 Mil (As of Dec. 2023)
View and export this data going back to 2007. Start your Free Trial

Diasorin SpA's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $1,678 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Diasorin SpA's Book Value per Share for the quarter that ended in Dec. 2023 was $31.44. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Diasorin SpA's Debt-to-Equity for the quarter that ended in Dec. 2023 was 0.78.

Diasorin SpA Total Stockholders Equity Historical Data

The historical data trend for Diasorin SpA's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diasorin SpA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Stockholders Equity
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 942.91 1,161.41 1,543.93 1,609.10 1,677.88

Diasorin SpA Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Stockholders Equity Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,609.10 1,634.30 1,619.65 1,657.67 1,677.88

Diasorin SpA  (OTCPK:DSRLF) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Diasorin SpA's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(1677.875-0)/53.36
=31.44

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Diasorin SpA's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(119.573 + 1181.032) / 1677.875
=0.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diasorin SpA Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Diasorin SpA's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Diasorin SpA (Diasorin SpA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Diasorin SpA (OTCPK:DSRLF) » Definitions » Total Stockholders Equity
Comparable Companies
HKSE:08070 HKSE:01379 HKSE:01273 HKSE:01591 HKSE:00380 HKSE:01629 HKSE:00544 HKSE:01758 HKSE:00379 HKSE:01720 TSE:2309 TMO DHR IQV IDXX XSWX:LONN A MTD ICLR ILMN
Traded in Other Exchanges
DIA:Italy 0GZX:UK 34D:Germany
Address
Via Crescentino Snc, Saluggia, Vercelli, ITA, 13040
Website
https://www.diasoringroup.com
Diasorin SpA is a biotechnology company engaged in developing, producing, and marketing reagent kits for laboratory diagnostics around the world. The business has focused on the immunodiagnostic market, molecular diagnostics, and Life Science sector. The company has a presence in Italy, Europe, North America, and the Rest of the world, where the majority of its revenue is from North America followed by Italy.